Fig. 1 · Structure

Documents & Downloads

Picropodophyllin

Cat. No. A12195 CAS 477-47-4
Picropodophyllin (AXL1717) is the first targeted oral small-molecule IGF-1 receptor inhibitor with no effect on the insulin receptor.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
IGF-1R 1 nM

Picropodophyllin Research Summary

This section summarizes 2 in vitro studies and 2 in vivo studies of Picropodophyllin from 3 published references. In vitro models include U2OS cells stably expressing GFP-LC3; RPMI-8226. In vivo models include nu/nu Balb/c mice with established A549 xenografts.

Picropodophyllin In Vitro Studies

Picropodophyllin induced GFP-LC3 puncta in U2OS cells stably expressing GFP-LC3, with induction altered in the reported knockout cells. In RPMI-8226 cells, Picropodophyllin reduced the number of viable cells in a dose- and time-dependent manner. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Puncta induction in cells expressing GFP-LC3

Cell-based study · U2OS cells stably expressing GFP-LC3 [1]

Picropodophyllin induced GFP-LC3 puncta in U2OS cells stably expressing GFP-LC3. Induction of GFP-LC3 puncta or LC3-II was lost in ATG5-/- cells, partially reduced in TFEB-/- or TFE3-/- cells, and strongly inhibited in TFEB-/- TFE3-/- double-knockout cells.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
the surface of GFP-LC3 positive punctaReported result PPP induced GFP-LC3 puncta; these effects were detectable at PPP concentrations of 2.5 to 10 µM. Induction of GFP-LC3 puncta or LC3-II by PPP was lost in ATG5-/- U2OS cells, was partially reduced in TFEB-/- or TFE3-/- cells, and strongly inhibited in TFEB-/- TFE3-/- double-knockout cells.[1]

Literature-Reported Treatment Conditions

Treatment concentration
1, 2.5, 5, 10 μM
Reported limits
Not stated in the sentences used: route, schedule, vehicle.
Methods and source locations

Compound reported in the paper: Picropodophyllin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Identification of PPP as a potent inducer of autophagic flux (S81, S83, S84); Figure 1 legend (S125, S133)

the surface of GFP-LC3 positive puncta: the surface of GFP-LC3 positive puncta; comparator: DMSO/Ctr — Results > Identification of PPP as a potent inducer of autophagic flux (S81, S83, S84); Figure 1 legend (S125)

Dose- and time-dependent reduction in cell viability

Cell-based study · RPMI-8226 [2]

In RPMI-8226 cells cultured with Picropodophyllin, the number of viable cells decreased in a dose- and time-dependent manner.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
cell viability; CellTiter-Glo AssayReported result 125 nM, 250 nM or 500 nM PPP; 24h and 48h: both compounds alone reduced the number of viable cells in a dose- and time-dependent manner.[2]

Literature-Reported Treatment Conditions

Treatment concentration
125 nM; 250 nM; 500 nM
Exposure duration
24h; 48h
Method
cultured with
Vehicle
dimethylsulfoxide
Methods and source locations

Compound reported in the paper: Picropodophyllin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

RESULTS > The IGF-1R inhibitor PPP potentiates the anti-myeloma effect of ABT-737 (S12); MATERIAL AND METHODS > Drugs (S77); MATERIAL AND METHODS > Cell viability assay (S83); Figure 2 legend (S135, S136, S137)

cell viability; CellTiter-Glo Assay: cell viability; CellTiter-Glo Assay; comparator: control cells — RESULTS > The IGF-1R inhibitor PPP potentiates the anti-myeloma effect of ABT-737 (S12); Figure 2 legend (S135, S136)

Picropodophyllin In Vivo Studies

Picropodophyllin administered daily in food strongly and significantly reduced BM plasmacytosis in 5T33MM-inoculated mice compared with vehicle. In mice with established A549 xenografts, Picropodophyllin administered by oral gavage increased the proportion of tumor cells in the G2/M phase compared with vehicle. [2,3]

Reduced bone marrow plasmacytosis in inoculated mice

Animal study · C57BL/KalwRij mice; 5T33MM inoculated mice; n=10 [2]

In 5T33MM-inoculated C57BL/KalwRij mice, Picropodophyllin administered daily in food produced a strong and significant reduction in BM plasmacytosis compared with vehicle.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
BM plasmacytosisBM plasmacytosis 51,4%[2]

Conditions shared by the study groups

Route
in food
Treatment course
daily; When the first mouse showed signs of morbidity all mice were sacrificed simultaneously
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Picropodophyllin 1.5 mg/kgvehicle group1.5 mg/kg PPP (daily in food): strong and significant reduction in BM plasmacytosis (51,4%) compared to the vehicle group.[2]
Picropodophyllin 1.5 mg/kg
Model: C57BL/KalwRij mice; 5T33MM inoculated mice; n=10
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Picropodophyllin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

RESULTS > In vivo anti-myeloma effects of ABT-737 in combination with PPP (S40); MATERIAL AND METHODS > 5T33MM model (S67, S70); Figure 6 legend (S167, S168)

BM plasmacytosis: BM plasmacytosis; comparator: vehicle group — RESULTS > In vivo anti-myeloma effects of ABT-737 in combination with PPP (S40); Figure 6 legend (S167, S168)

Picropodophyllin 1.5 mg/kg · RESULTS > In vivo anti-myeloma effects of ABT-737 in combination with PPP (S40); Figure 6 legend (S167, S168)

Increased tumor cell accumulation in the G2/M phase

Animal study · nu/nu Balb/c mice with established A549 xenografts [3]

In nu/nu Balb/c mice with established A549 xenografts, Picropodophyllin administered by oral gavage increased the proportion of tumor cells in the G2/M phase compared with vehicle.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
flow cytometric analysis of cell cycle phase distributionG2/M phase accumulation 1.5 to 3-fold increase[3]

Conditions shared by the study groups

Route
oral gavage
Treatment course
at 0, 12 and 24 h; At 3 h after the last treatment
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Picropodophyllin 40 mg/kgvehicle (7.5 mL/kg)PPP (40 mg/kg) at 0, 12 and 24 h: PPP induced a 1.5 to 3-fold increase of tumor cells in the G2/M phase.[3]
Picropodophyllin 40 mg/kg
Model: nu/nu Balb/c mice with established A549 xenografts
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Picropodophyllin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

RESULTS > PPP reduced viability and induced G2/M arrest in cancer cell lines independent of IGF-1R (S9); MATERIALS AND METHODS > A549 xenograft model (S80, S81, S82); Figure 1 legend (S126, S128)

flow cytometric analysis of cell cycle phase distribution: flow cytometric analysis of cell cycle phase distribution; comparator: vehicle (7.5 mL/kg) — RESULTS > PPP reduced viability and induced G2/M arrest in cancer cell lines independent of IGF-1R (S9); MATERIALS AND METHODS > A549 xenograft model (S81); Figure 1 legend (S128)

Picropodophyllin 40 mg/kg · RESULTS > PPP reduced viability and induced G2/M arrest in cancer cell lines independent of IGF-1R (S9); MATERIALS AND METHODS > A549 xenograft model (S81, S82)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 477-47-4
Formula C22H22O8
Molecular Weight 414.4
Synonyms AXL1717
SMILES
COC1=CC(=CC(=C1OC)OC)[C@H]2[C@H]3[C@H](COC3=O)[C@H](C4=CC5=C(C=C24)OCO5)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Warmed: 79 mg/mL (190.63 mM)
Water Insoluble
Ethanol Warmed: 1 mg/mL

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Picropodophyllin Research References

  1. [1] Wu Q, Tian AL, Li B, et al. IGF1 receptor inhibition amplifies the effects of cancer drugs by autophagy and immune-dependent mechanisms. J Immunother Cancer (2021). PMID: 34127545 DOI: 10.1136/jitc-2021-002722 Source material
  2. [2] Bieghs L, Lub S, Fostier K, et al. The IGF-1 receptor inhibitor picropodophyllin potentiates the anti-myeloma activity of a BH3-mimetic. Oncotarget (2014). PMID: 25008202 DOI: 10.18632/oncotarget.1933 Source material
  3. [3] Waraky A, Akopyan K, Parrow V, et al. Picropodophyllin causes mitotic arrest and catastrophe by depolymerizing microtubules via insulin-like growth factor-1 receptor-independent mechanism. Oncotarget (2014). PMID: 25268741 DOI: 10.18632/oncotarget.2292 Source material

Added to your cart

View Cart Checkout
Loading...